Pacira BioSciences PCRX
NASDAQ PCRX
$25.21 +0.20 (+0.80%)
At close: Oct 2, 2026 · 4:00 PM EDT

Pacira BioSciences (PCRX) Other Accumulated Expenses (2011 - 2012)

Updated

Pacira BioSciences' Other Accumulated Expenses was $360,000 in Q4 2012, up 4.3% from $345,000 a year earlier.

Analysis

Pacira BioSciences (PCRX) Other Accumulated Expenses (2011 - 2012) Analysis & Trends

  • In earlier years, Other Accumulated Expenses was $345,000 in FY2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Pacira BioSciences 1.00 Bn 65.95 Mn 148.24 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2012 360,000.00
Dec 31, 2011 345,000.00
API Access

Pacira BioSciences Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=PCRX&period=max&api_key=YOUR_API_KEY